<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methadone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00333</strong>&#160; (APRD00485)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3).</p>
<p>In Australia methadone is a Schedule 8 (controlled) drug.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00333/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00333/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00333.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00333.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00333.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00333.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00333.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00333">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(+/-)-Methadone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>(&#177;)-methadone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>6-Dimethylamino-4,4-diphenyl-3-heptanone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>dl-Methadone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Methadone Hydrochloride</strong>
          <div class="cas">1095-90-5</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000346/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000346/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: FJQXCDYVZAHXNS-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 345.18594223</li>
              <li>Average Mass: 345.906</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000346">DBSALT000346</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Adolan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Depridol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>DISKETS</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dolophine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Heptadon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Heptanon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ketalgin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mephenon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>METHADOSE</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Physeptone</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Polamidon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/analgesics-opioid">Analgesics, Opioid</a></li>
<li><a href="/mesh/narcotics">Narcotics</a></li>
<li><a href="/mesh/antitussive-agents">Antitussive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>76-99-3</td></tr><tr><th>Weight</th><td>Average: 309.4452<br>Monoisotopic: 309.209264491</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>27</sub>NO</td></tr><tr><th>InChI Key</th><td>USSIQXCVUWKGNF-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">6-(dimethylamino)-4,4-diphenylheptan-3-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Diphenylmethanes</td></tr><tr><th>Direct parent</th><td>Diphenylmethanes</td></tr><tr><th>Alternative parents</th><td>Phenylpropylamines; Tertiary Amines; Ketones; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>phenylpropylamine; ketone; tertiary amine; enolate; polyamine; amine; organonitrogen compound; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of dry cough, drug withdrawal syndrome, opioid type drug dependence, and pain.</td></tr><tr><th>Pharmacodynamics</th><td>Methadone is a synthetic opioid analgesic with multiple actions quantitatively similar to those at morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, Methadone is more active and more toxic than morphine. Methadone is indicated for relief of severe pain, for detoxification treatment of narcotic addiction, and for temporary maintenance treatment of narcotic addiction. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The Methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.</td></tr><tr><th>Mechanism of action</th><td>Methadone is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The principal therapeutic uses for methadone are for analgesia and for detoxification or maintenance in opioid addiction. The methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown. Other NMDA receptor antagonists have been shown to produce neurotoxic effects in animals.</td></tr><tr><th>Absorption</th><td>Well absorbed following oral administration. The bioavailability of methadone ranges between 36 to 100%.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1.0 to 8.0 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>In plasma, methadone is predominantly bound to &#945;1-acid glycoprotein (85% to 90%).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Methadone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00181">2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/182">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00181">2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET01087">2-Ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1155">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>The elimination of methadone is mediated by extensive biotransformation, followed by renal and fecal excretion. 
Unmetabolized methadone and its metabolites are excreted in urine to a variable degree.</td></tr><tr><th>Half life</th><td>24-36 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>1.4 to 126 L/h</li>
</ul></td></tr><tr><th>Toxicity</th><td>In severe overdosage, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Methadone Action Pathway</td><td>Drug action</td></tr><tr><td>Methadone Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00624?highlight%5Bcompounds%5D%5B%5D=DB00333&amp;highlight%5Bproteins%5D%5B%5D=DB00333">SMP00624</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9968</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9772</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7841</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6224</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7627</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9101</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5851</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7822</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7743</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.66</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5312</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.864</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.5449</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8177</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5507</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6586</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.946
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Carcinogens  
        </td>
        <td>
            0.6315
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9888
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.5250 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.947
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7606
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Roxane laboratories inc</li>
<li>Vistapharm inc</li>
<li>Mallinckrodt chemical inc</li>
<li>Bioniche pharma usa llc</li>
<li>Sandoz inc</li>
<li>Mallinckrodt inc</li>
<li>The pharmanetwork llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aaipharma.com">AAIPharma Inc.</a></li>
<li><a href="http://www.bionichepharmausa.com">Bioniche Pharma</a></li>
<li><a href="http://www.bpipack.com">Blenheim Pharmacal</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>D.M. Graham Laboratories Inc.</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.vistapharm.com">Vistapharm Inc.</a></li>
<li><a href="http://www.xanodyne.com">Xanodyne Pharmaceuticals Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Oral</td><td></td></tr><tr><td>Solution</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01351">Amobarbital</a></td><td>The barbiturate, amobarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>The protease inhibitor, amprenavir, may decrease the effect of methadone.</td></tr><tr><td><a href="/drugs/DB01352">Aprobarbital</a></td><td>The barbiturate, aprobarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>The barbiturate, butabarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>The barbiturate, butalbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB01353">Butethal</a></td><td>The barbiturate, butethal, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the serum level of methadone. Monitor for changes in the therapeutic and adverse effects of methadone if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine, a moderate CYP3A4 inhibitor, may increase the serum concentration of metahdone, a CYP3A4 substrate. Monitor for changes in the therapeutic and adverse effects of methadone if cimetidine is initiatied, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>The barbiturate, dihydroquinidine barbiturate, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Efavirenz may decrease the serum concentration of methadone by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of methadone if efavirenz is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Methadone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. </td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The hydantoin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Methadone, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor methadone therapy for decrease effectiveness and symptoms of withdrawal.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Fluvoxamine increases the effect and toxicity of methadone</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>The protease inhibitor, fosamprenavir, may decrease the effect of methadone.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The hydantoin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB01354">Heptabarbital</a></td><td>The barbiturate, heptabarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB01355">Hexobarbital</a></td><td>The barbiturate, hexobarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The hydantoin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00474">Methohexital</a></td><td>The barbiturate, methohexital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00849">Methylphenobarbital</a></td><td>The barbiturate, methylphenobarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00238">Nevirapine</a></td><td>The antiretroviral agent decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>The barbiturate, pentobarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>The barbiturate, phenobarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The hydantoin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The barbiturate, primidone, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>The barbiturate, quinidine barbiturate, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>The rifamycin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>The rifamycin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB01201">Rifapentine</a></td><td>The rifamycin decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Dose adjustment and clinical monitoring of rilpivirine may be necessary if coadministered with methadone. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>The protease inhibitor, ritonavir, may decrease the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00418">Secobarbital</a></td><td>The barbiturate, secobarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort decreases levels/effect of methadone</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00306">Talbutal</a></td><td>The barbiturate, talbutal, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Methadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Methadone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methadone is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir decreases exposure of methane by 30% however opioid withdrawal was not observed in patients. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Methadone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methadone if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>Thiopental may decrease the effect of Methadone by increasing Methadone metabolism. Methadone withdrawal may occur. </td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, decreases the Methadone concentration. Monitor for symptoms of opiate withdrawal. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Methadone may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Methadone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methadone by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of methadone if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00495">Zidovudine</a></td><td>Methadone increases the effect and toxicity of zidovudine</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals. Avoid alcohol. Usually diluted in fruit juice.</li></ul></td></tr></tbody></table>